Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01655693|
Recruitment Status : Completed
First Posted : August 2, 2012
Last Update Posted : September 2, 2019
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis and with good liver functions are eligible. Only those who can not benefit from treatment for which efficacy is demonstrated are eligible.
These patients are usually proposed either best standard of care (BSC) or participation to clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2 or DT at 30 mg/m2 or the BSC.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Hepatocellular||Drug: Doxorubicin Drug: Best Standard of Care||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||398 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.|
|Actual Study Start Date :||June 2012|
|Actual Primary Completion Date :||May 2017|
|Actual Study Completion Date :||February 2019|
Experimental: Doxorubicin Transdrug (DT) at 20mg/m2
DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
Other Name: Doxorubicin Transdrug (DT) at 20mg/m2
Experimental: Doxorubicin Transdrug (DT) at 30 mg/m2
DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
Other Name: Doxorubicin Transdrug (DT) at 30mg/m2
Active Comparator: Best Standard of Care
Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
Drug: Best Standard of Care
- Overall survival(OS) in each group [ Time Frame: At 1 year (expected average) ]Survival status will be collected at each visit (at least every 2 weeks) during the study treatment period and then every 3 months until death for an expected average of 1 year.
- Incidence and severity of all Treatment Emergent Adverse Events according to NCI-CTC v4.0 scale in each group [ Time Frame: Until 1 month after last treatment intake ]Adverse events will be collected at each visit (at least every 2 weeks) during the study treatment period, and then 1 month after the last treatment intake for an expected average of 6 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655693
Show 70 Study Locations
|Principal Investigator:||Philippe Merle, MD||Croix-Rousse Hospital - Lyon-France|